A detailed history of Lindbrook Capital, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 1,914 shares of AVXL stock, worth $16,517. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,914
Previous 1,805 6.04%
Holding current value
$16,517
Previous $7,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$4.11 - $7.04 $447 - $767
109 Added 6.04%
1,914 $10,000
Q2 2024

Jul 31, 2024

BUY
$3.39 - $5.02 $5,481 - $8,117
1,617 Added 860.11%
1,805 $7,000
Q1 2024

Apr 25, 2024

SELL
$4.55 - $6.75 $1,915 - $2,841
-421 Reduced 69.13%
188 $0
Q4 2023

Jan 31, 2024

BUY
$5.04 - $9.95 $3,069 - $6,059
609 New
609 $5,000
Q3 2023

Oct 25, 2023

BUY
$6.55 - $9.37 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022

BUY
$8.9 - $12.86 $347 - $501
39 New
39 $0

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.